Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • District of Columbia - United States Medical cannabis bill increasing access becomes law…
  • United States - Washington Interstate cannabis trade bill passes Senate and heads to House…
  • South Dakota - United States Governor vetoes industrial hemp revision bill…
  • South Dakota - United States Medical cannabis use prohibited if pregnant or breastfeeding…
  • South Dakota - United States Governor signs bill on medical cannabis qualifying conditions…
  • Oklahoma - United States Medical cannabis-related bill passes Senate…
  • Kentucky - United States Delta-8 THC bill signed by governor and becomes law…
  • Europe EC reveals environmental claims proposal…
  • Spain Parties rally behind Podemos proposal for hemp regulation…
  • Maryland - United States Personal use cannabis good, ‘volume dealing’ bad, House says…
  • North Dakota - United States Legislature approves easier cannabis rules for over-65s in hospices…
  • New Hampshire - United States House backs home growing for medical cannabis patients…
View all
News analysis

Jazz Pharmaceuticals buys Epidiolex manufacturer GW Pharma for $7.2bn

Written by || 3rd February 2021 || News analysis | Companies | Health and science | Europe Ireland North America United Kingdom United States

GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents
CBD-based epilepsy drug Epidyolex gets the green light from Europe
Trials and research into the healing potential of cannabinoids continue
Pharma gets bigger with approval for new cannabinoid-based treatments

CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

© 2023 Tamarind Media Limited (T/A CannIntelligence)
CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.